GlassScriptPhysician profile
Lanning R Newell
NPI 1114926250
$6,363.51
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,389 · 2020: $823 · 2021: $1,598 · 2022: $1,591 · 2023: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,938.49 | 2019-2023 | |
| Gilead Sciences, INC. | $896.22 | 2019-2023 | |
| Pfizer INC. | $667.89 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $415.99 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $401.51 | 2019-2023 | Xifaxan, Trulance, Plenvu |
| Intercept Pharmaceuticals, INC. | $310.42 | 2019-2023 | Ocaliva |
| Redhill Biopharma INC. | $264.84 | 2021-2022 | |
| Celgene Corporation | $239.92 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $232.75 | 2019-2023 | Stelara |
| Ferring Pharmaceuticals INC. | $178.98 | 2019-2023 | Rebyota |
| Janssen Scientific Affairs, LLC | $124.99 | 2020 | |
| Amgen INC. | $107.43 | 2021-2023 | Amjevita, Avsola |
| Braintree Laboratories, INC. | $102.48 | 2020-2022 | |
| Daiichi Sankyo INC. | $84.13 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $68.71 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $64.98 | 2019-2022 | |
| Ucb, INC. | $55.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $47.41 | 2019 | |
| Intra-Sana Laboratories | $38.03 | 2021 | |
| Organon LLC | $32.23 | 2021-2023 | Renflexis, Hadlima |
| E.R. Squibb & Sons, L.L.C. | $26.71 | 2021 | |
| Shire North American Group INC | $17.26 | 2019 | |
| Qol Medical, LLC | $16.28 | 2023 | Sucraid |
| Evoke Pharma, INC. | $16.14 | 2021 | |
| Ironwood Pharmaceuticals, INC | $14.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lanning Newell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.